Yipinhong Pharmaceutical Co Ltd Class A - Asset Resilience Ratio
Yipinhong Pharmaceutical Co Ltd Class A (300723) has an Asset Resilience Ratio of 0.66% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Yipinhong Pharmaceutical Co Ltd Class A to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Asset Resilience Ratio has changed over time. See 300723 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300723 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥31.00 Million | 0.66% |
| Total Liquid Assets | CN¥31.00 Million | 0.66% |
Asset Resilience Insights
- Limited Liquidity: Yipinhong Pharmaceutical Co Ltd Class A maintains only 0.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yipinhong Pharmaceutical Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Yipinhong Pharmaceutical Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Yipinhong Pharmaceutical Co Ltd Class A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Yipinhong Pharmaceutical Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | CN¥4.75 Million ≈ $694.52K |
CN¥4.40 Billion ≈ $644.46 Million |
-0.81pp |
| 2023-12-31 | 0.92% | CN¥40.44 Million ≈ $5.92 Million |
CN¥4.41 Billion ≈ $644.63 Million |
-0.84pp |
| 2022-12-31 | 1.76% | CN¥72.19 Million ≈ $10.56 Million |
CN¥4.10 Billion ≈ $599.73 Million |
+1.36pp |
| 2021-12-31 | 0.41% | CN¥15.03 Million ≈ $2.20 Million |
CN¥3.70 Billion ≈ $542.07 Million |
-0.20pp |
| 2020-12-31 | 0.61% | CN¥13.00 Million ≈ $1.90 Million |
CN¥2.15 Billion ≈ $313.90 Million |
-1.38pp |
| 2019-12-31 | 1.98% | CN¥35.60 Million ≈ $5.21 Million |
CN¥1.79 Billion ≈ $262.64 Million |
-- |
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxia… Read more